Novo Nordisk Sales Guidance and Wegovy Pill in Focus -- Market Talk

Dow Jones04-10 17:00

0900 GMT - Novo Nordisk's sales guidance and momentum of its Wegovy weight-loss pill will be key focus points in theDanish pharma giant's first-quarter report, UBS analyst Matthew Weston writes. Wegovy pill prescription growth continues to impress and UBS expects the pill generated first-quarter sales of $235 million. There could be potential for an upgrade to group sales guidance at the results, the bank says. "A key assumption for Novo's guidance was expected limited sequential volume growth in Wegovy pen, which through 1Q has seen a strong pick up." However, uncertainty remains around the impact of Eli Lilly's rival obesity pill launch and the sustainability of oral Wegovy momentum throughout the yearm the bank says. Gross margin development is also a key unknown, UBS adds. Shares rise 1.8%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 05:00 ET (09:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626543193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626543193","market":"sh","top_or_hot":-1,"title":"Novo Nordisk Sales Guidance and Wegovy Pill in Focus -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0900 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s sales guidance and momentum of its Wegovy weight-loss pill will be key focus points in theDanish pharma giant's first-quarter report, UBS analyst Matthew Weston writes. Wegovy pill prescription growth continues to impress and UBS expects the pill generated first-quarter sales of $235 million. There could be potential for an upgrade to group sales guidance at the results, the bank says. \"A key assumption for Novo's guidance was expected limited sequential volume growth in Wegovy pen, which through 1Q has seen a strong pick up.\" However, uncertainty remains around the impact of Eli Lilly's rival obesity pill launch and the sustainability of oral Wegovy momentum throughout the yearm the bank says. Gross margin development is also a key unknown, UBS adds. Shares rise 1.8%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 05:00 ET (09:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Sales Guidance and Wegovy Pill in Focus -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Sales Guidance and Wegovy Pill in Focus -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 17:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0900 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s sales guidance and momentum of its Wegovy weight-loss pill will be key focus points in theDanish pharma giant's first-quarter report, UBS analyst Matthew Weston writes. Wegovy pill prescription growth continues to impress and UBS expects the pill generated first-quarter sales of $235 million. There could be potential for an upgrade to group sales guidance at the results, the bank says. \"A key assumption for Novo's guidance was expected limited sequential volume growth in Wegovy pen, which through 1Q has seen a strong pick up.\" However, uncertainty remains around the impact of Eli Lilly's rival obesity pill launch and the sustainability of oral Wegovy momentum throughout the yearm the bank says. Gross margin development is also a key unknown, UBS adds. Shares rise 1.8%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 05:00 ET (09:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626543193","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626543193","pubTimestamp":1775811600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0900 GMT - Novo Nordisk's sales guidance and momentum of its Wegovy weight-loss pill will be key focus points in theDanish pharma giant's first-quarter report, UBS analyst Matthew Weston writes. Wegovy pill prescription growth continues to impress and UBS expects the pill generated first-quarter sales of $235 million. There could be potential for an upgrade to group sales guidance at the results, the bank says. \"A key assumption for Novo's guidance was expected limited sequential volume growth inWegovy pen, which through 1Q has seen a strong pick up.\" However, uncertainty remains around the impact of Eli Lilly's rival obesity pill launch and the sustainability of oral Wegovy momentum throughout the yearm the bank says. Gross margin development is also a key unknown, UBS adds. Shares rise 1.8%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVOX":"2倍做多NVO ETF-Defiance","BK4007":"制药","BK4599":"减肥药","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","NVOH":"Novo Nordisk A/S B Shares ADRhedged"},"translate_title":"诺和诺德销售指引和Wegovy药丸成为焦点——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.97,"NVOX":0.6,"NVOH":0.6},"content_text":"0900 GMT - Novo Nordisk's sales guidance and momentum of its Wegovy weight-loss pill will be key focus points in theDanish pharma giant's first-quarter report, UBS analyst Matthew Weston writes. Wegovy pill prescription growth continues to impress and UBS expects the pill generated first-quarter sales of $235 million. There could be potential for an upgrade to group sales guidance at the results, the bank says. \"A key assumption for Novo's guidance was expected limited sequential volume growth in Wegovy pen, which through 1Q has seen a strong pick up.\" However, uncertainty remains around the impact of Eli Lilly's rival obesity pill launch and the sustainability of oral Wegovy momentum throughout the yearm the bank says. Gross margin development is also a key unknown, UBS adds. Shares rise 1.8%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 05:00 ET (09:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626543193","isCrawlerRequest":true}